JP2021532165A5 - - Google Patents
Info
- Publication number
- JP2021532165A5 JP2021532165A5 JP2021510499A JP2021510499A JP2021532165A5 JP 2021532165 A5 JP2021532165 A5 JP 2021532165A5 JP 2021510499 A JP2021510499 A JP 2021510499A JP 2021510499 A JP2021510499 A JP 2021510499A JP 2021532165 A5 JP2021532165 A5 JP 2021532165A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound represented
- diseases
- crystalline
- forms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023023091A JP7651198B2 (ja) | 2018-05-04 | 2023-02-17 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
| JP2025035420A JP2025074350A (ja) | 2018-05-04 | 2025-03-06 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/085617 WO2019210511A1 (zh) | 2018-05-04 | 2018-05-04 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023091A Division JP7651198B2 (ja) | 2018-05-04 | 2023-02-17 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021532165A JP2021532165A (ja) | 2021-11-25 |
| JP2021532165A5 true JP2021532165A5 (enExample) | 2022-07-08 |
| JP7275253B2 JP7275253B2 (ja) | 2023-05-17 |
Family
ID=68387039
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510499A Active JP7275253B2 (ja) | 2018-05-04 | 2018-05-04 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
| JP2023023091A Active JP7651198B2 (ja) | 2018-05-04 | 2023-02-17 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
| JP2025035420A Pending JP2025074350A (ja) | 2018-05-04 | 2025-03-06 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023023091A Active JP7651198B2 (ja) | 2018-05-04 | 2023-02-17 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
| JP2025035420A Pending JP2025074350A (ja) | 2018-05-04 | 2025-03-06 | Ｓ１ｐ１受容体アゴニストの付加塩およびその結晶形態、ならびに薬学的組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11512078B2 (enExample) |
| EP (2) | EP4353719B1 (enExample) |
| JP (3) | JP7275253B2 (enExample) |
| KR (2) | KR102672632B1 (enExample) |
| AU (1) | AU2018421487B2 (enExample) |
| CA (1) | CA3099196A1 (enExample) |
| ES (1) | ES2978392T3 (enExample) |
| IL (3) | IL278464B2 (enExample) |
| MX (1) | MX2020011665A (enExample) |
| NZ (1) | NZ770323A (enExample) |
| SG (1) | SG11202010969UA (enExample) |
| WO (1) | WO2019210511A1 (enExample) |
| ZA (1) | ZA202007347B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL278464B2 (en) * | 2018-05-04 | 2024-10-01 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
| CA3201000A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533058A (ja) * | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN103450171B (zh) | 2013-09-22 | 2015-07-08 | 苏州康乃德生物医药有限公司 | 一种免疫调节化合物、其用途和包含其的药物组合物 |
| CN105315266B (zh) | 2014-08-01 | 2019-10-01 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 |
| CN105348276B (zh) | 2014-08-22 | 2020-05-26 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法 |
| CN112778290B (zh) * | 2017-01-11 | 2022-12-06 | 苏州康乃德生物医药有限公司 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
| IL278464B2 (en) * | 2018-05-04 | 2024-10-01 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
-
2018
- 2018-05-04 IL IL278464A patent/IL278464B2/en unknown
- 2018-05-04 NZ NZ770323A patent/NZ770323A/en unknown
- 2018-05-04 EP EP24155906.1A patent/EP4353719B1/en active Active
- 2018-05-04 AU AU2018421487A patent/AU2018421487B2/en active Active
- 2018-05-04 KR KR1020207034174A patent/KR102672632B1/ko active Active
- 2018-05-04 EP EP18917186.1A patent/EP3792258B1/en active Active
- 2018-05-04 MX MX2020011665A patent/MX2020011665A/es unknown
- 2018-05-04 US US17/052,160 patent/US11512078B2/en active Active
- 2018-05-04 WO PCT/CN2018/085617 patent/WO2019210511A1/zh not_active Ceased
- 2018-05-04 IL IL312512A patent/IL312512B2/en unknown
- 2018-05-04 CA CA3099196A patent/CA3099196A1/en active Pending
- 2018-05-04 SG SG11202010969UA patent/SG11202010969UA/en unknown
- 2018-05-04 KR KR1020247018420A patent/KR20240094023A/ko active Pending
- 2018-05-04 ES ES18917186T patent/ES2978392T3/es active Active
- 2018-05-04 JP JP2021510499A patent/JP7275253B2/ja active Active
-
2020
- 2020-11-25 ZA ZA2020/07347A patent/ZA202007347B/en unknown
-
2022
- 2022-10-06 US US17/961,270 patent/US12202822B2/en active Active
-
2023
- 2023-02-17 JP JP2023023091A patent/JP7651198B2/ja active Active
-
2024
- 2024-12-11 US US18/977,539 patent/US20250320200A1/en active Pending
-
2025
- 2025-03-06 JP JP2025035420A patent/JP2025074350A/ja active Pending
- 2025-09-29 IL IL323665A patent/IL323665A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020033360A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| IL274943B1 (en) | Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases | |
| JP2018518537A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2021525729A5 (enExample) | ||
| JP2022550919A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2021512906A5 (enExample) | ||
| JP2022521233A5 (enExample) | ||
| JP2022507533A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| JP2015508765A5 (enExample) | ||
| JP2022519007A5 (enExample) | ||
| JP2021532165A5 (enExample) | ||
| JP2016528171A5 (enExample) | ||
| JP2013536206A5 (enExample) | ||
| JP5745526B2 (ja) | 糖尿病の予防のためのスルホンアミド | |
| AU2019336248A1 (en) | New use of R-enantiomer of adrenergic β2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations | |
| JP2020535139A (ja) | シポニモドの投与レジメン | |
| Iversen | Late results from continuous treatment of thyrotoxicosis with methylthiouracil | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2022505184A5 (enExample) | ||
| CN114588164B (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
| JPH01265027A (ja) | 肝疾患治療剤 | |
| JP7408643B2 (ja) | カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用 |